2020 American Transplant Congress
Strong Engagement of CD137 Suppresses Graft-Versus-Host Disease Through Dendritic Cells
*Purpose: We previously demonstrated that anti-CD137 agonist prevent acute graft-versus-host disease (GVHD) and chronic GVHD in the parent-into-unirradiated F1 acute or chronic GVHD model. Although…2020 American Transplant Congress
Belatacept versus Tacrolimus Combined with Antithymocyte Globulin in Kidney Transplantation
1Swedish Medical Center, Seattle, WA, 2SUNY, Brooklyn, NY, 3Permanente Medical Group, Oakland, CA
*Purpose: Belatacept (BELA) used for maintenance immunosuppression (IS) after kidney transplant (KT) shows similar graft and patient survival, but improved allograft function, despite more rejection…2020 American Transplant Congress
Donor Mesenchymal Stem Cells in Combination with Co-Stimulation Blockade Prolong Allograft Survival
Surgery and Transplantation, Emory University, Atlanta, GA
*Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy and potential alternative to calcineurin inhibitors in solid organ transplantation. Despite recent advancements, CoB…2020 American Transplant Congress
Ifnar Signaling on Myeloid Cells Does Not Contribute to Costimulation Independent Transplant Rejection
*Purpose: Costimulation blockade (CoB) is a promising new strategy that provides a more targeted therapy with fewer side effects compared to traditional transplant immunosuppressants, leading…2020 American Transplant Congress
Targeting Th17: TIGIT as a Key Regulator of Tregs/Th17 Cells in Belatacept Resistant Rejection
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Belatacept resistant-rejection (BRR) is a major barrier to the widespread adoption of immune checkpoint blockade therapeutics in transplantation. Our lab has shown that patients…2020 American Transplant Congress
Conversion to Belatacept in HIV(+) Renal Transplant Recipients
Mount Sinai Hospital, New York, NY
*Purpose: HIV(+) renal transplant recipients were excluded from phase III trials of belatacept, and currently there are only scattered case reports.*Methods: This was a single…2020 American Transplant Congress
Desensitization for Deceased Donor Transplantation: Testing a New Paradigm in the Nonhuman Primate
*Purpose: Desensitization regimens have rarely been applied to deceased donor allotransplantation. We hypothesized that belatacept monotherapy during a simulated deceased donor waiting list period would…2020 American Transplant Congress
HLA Cross-Dressing of Dendritic Cells by Maternal Exosomes is Associated with PD-L1 Expression in Newborns
1University of Wisconsin-Madison, Madison, WI, 2Fred Hutchinson Cancer Research Center, Seattle, WA
*Purpose: Recipients of a kidney transplant from a haplo-identical sibling had accelerated early acute rejection episodes, followed by improved long-term graft survival if the transplant…2020 American Transplant Congress
Agonistic Anti-CD272 Antibody (6B2) Suppressed Donor Specific Antibody Through Inducible Regulatory T Cells
*Purpose: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) is a coinhibitory molecule and may play an important role in alloimmune responses. We…2020 American Transplant Congress
Three Year Post Co-Stimulation Blocking Agent (Belatacept) Switch Outcomes of Kidney Transplant Patients Diagnosed with Post-Transplant Thrombotic Microangiopathy
*Purpose: Thrombotic microangiopathy (TMA) can happen after kidney transplant. It may occur de novo or as a recurrent disease. De novo is usually associated with…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 30
- Next Page »